Steven J. Charlton

5.0k total citations
85 papers, 3.8k citations indexed

About

Steven J. Charlton is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Physiology. According to data from OpenAlex, Steven J. Charlton has authored 85 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 26 papers in Cellular and Molecular Neuroscience and 16 papers in Physiology. Recurrent topics in Steven J. Charlton's work include Receptor Mechanisms and Signaling (57 papers), Neuropeptides and Animal Physiology (16 papers) and Monoclonal and Polyclonal Antibodies Research (11 papers). Steven J. Charlton is often cited by papers focused on Receptor Mechanisms and Signaling (57 papers), Neuropeptides and Animal Physiology (16 papers) and Monoclonal and Polyclonal Antibodies Research (11 papers). Steven J. Charlton collaborates with scholars based in United Kingdom, Switzerland and United States. Steven J. Charlton's co-authors include Georges Vauquelin, David A. Sykes, Elizabeth M. Rosethorne, Mark R. Dowling, Michael R. Boarder, J. Robert Lane, Jonathan A. Javitch, Martin C. Michel, Robin A. Fairhurst and Juliet Leighton-Davies and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and PLoS ONE.

In The Last Decade

Steven J. Charlton

82 papers receiving 3.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steven J. Charlton United Kingdom 34 2.5k 1.3k 704 462 433 85 3.8k
Jillian G. Baker United Kingdom 23 3.1k 1.2× 1.9k 1.5× 424 0.6× 498 1.1× 127 0.3× 56 3.9k
Lauren T. May Australia 37 3.0k 1.2× 1.6k 1.2× 156 0.2× 301 0.7× 386 0.9× 89 4.0k
Richard A. Bond United States 37 4.0k 1.6× 1.8k 1.4× 1.7k 2.3× 169 0.4× 322 0.7× 99 6.2k
Raymond B. Penn United States 44 4.6k 1.8× 2.1k 1.7× 2.2k 3.1× 222 0.5× 813 1.9× 117 7.0k
Misty M. Attwood Sweden 14 2.6k 1.0× 854 0.7× 297 0.4× 337 0.7× 204 0.5× 22 3.6k
J.W. Black United Kingdom 29 2.2k 0.9× 1.3k 1.0× 551 0.8× 174 0.4× 290 0.7× 87 3.8k
Emma L. Veale United Kingdom 31 2.4k 0.9× 1.2k 1.0× 519 0.7× 80 0.2× 281 0.6× 57 4.4k
Makoto R. Hara United States 17 2.9k 1.2× 913 0.7× 958 1.4× 100 0.2× 378 0.9× 19 4.2k
Camilo Rojas United States 37 1.9k 0.8× 636 0.5× 623 0.9× 542 1.2× 228 0.5× 108 4.6k
Finn Olav Levy Norway 36 2.5k 1.0× 1.1k 0.9× 382 0.5× 145 0.3× 363 0.8× 131 4.1k

Countries citing papers authored by Steven J. Charlton

Since Specialization
Citations

This map shows the geographic impact of Steven J. Charlton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven J. Charlton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven J. Charlton more than expected).

Fields of papers citing papers by Steven J. Charlton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven J. Charlton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven J. Charlton. The network helps show where Steven J. Charlton may publish in the future.

Co-authorship network of co-authors of Steven J. Charlton

This figure shows the co-authorship network connecting the top 25 collaborators of Steven J. Charlton. A scholar is included among the top collaborators of Steven J. Charlton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven J. Charlton. Steven J. Charlton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lim, Herman D., Jacqueline R. Glenn, Steven J. Charlton, et al.. (2025). Identification of a Lipid-Exposed Extrahelical Binding Site for Positive Allosteric Modulators of the Dopamine D2 Receptor. ACS Chemical Neuroscience. 16(12). 2295–2311. 1 indexed citations
2.
Williams, Huw E. L., et al.. (2023). Design, Synthesis, and Application of Fluorescent Ligands Targeting the Intracellular Allosteric Binding Site of the CXC Chemokine Receptor 2. Journal of Medicinal Chemistry. 66(18). 12911–12930. 10 indexed citations
3.
Sykes, David A., Mireia Jiménez‐Rosés, John Reilly, et al.. (2022). Exploring the kinetic selectivity of drugs targeting the β 1 ‐adrenoceptor. Pharmacology Research & Perspectives. 10(4). 6 indexed citations
4.
May, Lauren T., et al.. (2021). Inhibition of the Proliferation of Human Lung Fibroblasts by Prostacyclin Receptor Agonists is Linked to a Sustained cAMP Signal in the Nucleus. Frontiers in Pharmacology. 12. 669227–669227. 23 indexed citations
5.
Kellam, Barrie, David A. Sykes, Ben Capuano, et al.. (2019). Structure–Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor. Journal of Medicinal Chemistry. 62(21). 9488–9520. 15 indexed citations
6.
7.
Sykes, David A. & Steven J. Charlton. (2018). Single Step Determination of Unlabeled Compound Kinetics Using a Competition Association Binding Method Employing Time-Resolved FRET. Methods in molecular biology. 1824. 177–194. 9 indexed citations
8.
Sykes, David A., Holly Moore, Nicholas D. Holliday, et al.. (2017). Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nature Communications. 8(1). 763–763. 150 indexed citations
9.
10.
Trifilieff, Alexandre, Brian Ethell, David A. Sykes, et al.. (2015). Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model. Toxicology and Applied Pharmacology. 287(1). 9–16. 4 indexed citations
11.
Sykes, David A., et al.. (2014). QAW039, a slowly dissociating CRTh2 antagonist with potential for improved clinical efficacy. European Respiratory Journal. 44(Suppl 58). P4074–P4074. 7 indexed citations
12.
13.
Nijmeijer, Saskia, Henry F. Vischer, Francesco Sirci, et al.. (2013). Detailed analysis of biased histamineH4receptor signalling byJNJ7777120 analogues. British Journal of Pharmacology. 170(1). 78–88. 27 indexed citations
14.
Poulin, Benoit, Adrian J. Butcher, Robert Pawlak, et al.. (2010). The M 3 -muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. Proceedings of the National Academy of Sciences. 107(20). 9440–9445. 121 indexed citations
15.
Rosethorne, Elizabeth M. & Steven J. Charlton. (2010). Agonist-Biased Signaling at the Histamine H4 Receptor: JNJ7777120 Recruits β-Arrestin without Activating G Proteins. Molecular Pharmacology. 79(4). 749–757. 96 indexed citations
16.
Charlton, Steven J., et al.. (2010). A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. British Journal of Pharmacology. 159(7). 1429–1439. 67 indexed citations
17.
Beattie, David T., Steven J. Charlton, Bernard Cuenoud, et al.. (2010). A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of β2-adrenoceptor agonists as inhaled long-acting bronchodilators. Bioorganic & Medicinal Chemistry Letters. 20(17). 5302–5307. 19 indexed citations
18.
Battram, Cliff H., Steven J. Charlton, Bernard Cuenoud, et al.. (2006). In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1 H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action. Journal of Pharmacology and Experimental Therapeutics. 317(2). 762–770. 128 indexed citations
19.
Turner, Robert J. & Steven J. Charlton. (2005). Assessing the Minimum Number of Data Points Required for Accurate IC 50 Determination. Assay and Drug Development Technologies. 3(5). 525–531. 18 indexed citations
20.
Hodgson, Simon T., et al.. (2004). Chemokines and drug discovery.. PubMed. 17(5). 335–8. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jillian G. Baker Breakdown of academic impact, for papers by Lauren T. May Breakdown of academic impact, for papers by Richard A. Bond Breakdown of academic impact, for papers by Raymond B. Penn Breakdown of academic impact, for papers by Misty M. Attwood Breakdown of academic impact, for papers by J.W. Black Breakdown of academic impact, for papers by Emma L. Veale Breakdown of academic impact, for papers by Makoto R. Hara Breakdown of academic impact, for papers by Camilo Rojas Breakdown of academic impact, for papers by Finn Olav Levy
Rankless by CCL
2026